zaleplon has been researched along with Depressive Disorder, Major in 3 studies
zaleplon: an azabicyclo(4.3.0)nonane; a nonbenzodiazepine; one of the so-called of Z drugs (zopiclone, eszopiclone, zolpidem, and zaleplon) for which there is some correlation with tumors; a hypnotic with less marked effect on psychomotor functions compared to lorazepam
zaleplon : A pyrazolo[1,5-a]pyrimidine having a nitrile group at position 3 and a 3-(N-ethylacetamido)phenyl substituent at the 7-position.
Depressive Disorder, Major: Disorder in which five (or more) of the following symptoms have been present during the same 2-week period and represent a change from previous functioning; at least one of the symptoms is either (1) depressed mood or (2) loss of interest or pleasure. Symptoms include: depressed mood most of the day, nearly every daily; markedly diminished interest or pleasure in activities most of the day, nearly every day; significant weight loss when not dieting or weight gain; Insomnia or hypersomnia nearly every day; psychomotor agitation or retardation nearly every day; fatigue or loss of energy nearly every day; feelings of worthlessness or excessive or inappropriate guilt; diminished ability to think or concentrate, or indecisiveness, nearly every day; or recurrent thoughts of death, recurrent suicidal ideation without a specific plan, or a suicide attempt. (DSM-5)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Major depressive disorder is also highly comorbid in this population, leading to further impairment." | 5.62 | Treatment of Insomnia with Zaleplon in HIV+ Significantly Improves Sleep and Depression. ( Goldschmied, JR; Kayser, MS; Morales, KH; Sengupta, A; Sharma, A; Taylor, L; Thase, ME; Weljie, A, 2021) |
| "Major depressive disorder is also highly comorbid in this population, leading to further impairment." | 1.62 | Treatment of Insomnia with Zaleplon in HIV+ Significantly Improves Sleep and Depression. ( Goldschmied, JR; Kayser, MS; Morales, KH; Sengupta, A; Sharma, A; Taylor, L; Thase, ME; Weljie, A, 2021) |
| "Although it has been claimed that insomnia causes an increased risk for depression, adequate controlled trials testing this hypothesis have not been available." | 1.34 | Greater incidence of depression with hypnotic use than with placebo. ( Kripke, DF, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Goldschmied, JR | 1 |
| Sengupta, A | 1 |
| Sharma, A | 1 |
| Taylor, L | 1 |
| Morales, KH | 1 |
| Thase, ME | 2 |
| Weljie, A | 1 |
| Kayser, MS | 1 |
| Liskow, B | 1 |
| Pikalov, A | 1 |
| Kripke, DF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A 6-week Open-Label Study of Treatment of Insomnia With Zaleplon in HIV Positive Patients With Comorbid Depression[NCT03489304] | Phase 2 | 20 participants (Actual) | Interventional | 2014-04-03 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Epworth Sleepiness Scale (ESS) is a validated sleep scale that quantifies daytime sleepiness across eight domains. The total score ranges from 0-24 where higher values indicate greater daytime sleepiness. (NCT03489304)
Timeframe: Measure at 6 weeks
| Intervention | score on a scale (Mean) |
|---|---|
| Zaleplon | 6.5 |
The Insomnia Severity Index is a validated sleep scale that measures clinical insomnia severity. The total score ranges from 0-28 where higher values indicate increased severity of insomnia. (NCT03489304)
Timeframe: Measure at 6 weeks
| Intervention | score on a scale (Mean) |
|---|---|
| Zaleplon | 11 |
The Quick Inventory of Depressive Symptomatology (QIDS) is a validated mood scale that quantifies depression symptoms. The total score ranges from 0-48, where higher values indicate greater depressive symptoms. (NCT03489304)
Timeframe: Measure at 6 weeks
| Intervention | score on a scale (Mean) |
|---|---|
| Zaleplon | 8.7 |
3 other studies available for zaleplon and Depressive Disorder, Major
| Article | Year |
|---|---|
Treatment of Insomnia with Zaleplon in HIV+ Significantly Improves Sleep and Depression.
Topics: Acetamides; Depression; Depressive Disorder, Major; Humans; Pyrimidines; Quality of Life; Sleep; Sle | 2021 |
Zaleplon overdose associated with sleepwalking and complex behavior.
Topics: Acetamides; Adolescent; Child Behavior Disorders; Depressive Disorder, Major; Drug Overdose; Drug Th | 2004 |
Greater incidence of depression with hypnotic use than with placebo.
Topics: Acetamides; Azabicyclo Compounds; Cross-Sectional Studies; Depressive Disorder, Major; Drug Prescrip | 2007 |